间充质干细胞联合胰岛细胞治疗1型糖尿病研究进展  

Cotransplantation of mesenchymal stem cells and islet in the treatment of type 1 diabetes mellitus:recent progress

作　　者：朱从元[1] 李建平[1] 

机构地区：[1]南京医科大学附属无锡第二医院肝胆外科,江苏省无锡市214000

出　　处：《世界华人消化杂志》2011年第24期2546-2550,共5页World Chinese Journal of Digestology

摘　　要：近年来,国内外兴起的胰岛移植术治疗1型糖尿病,因炎症介导的免疫反应以及营养因子缺乏而导致移植后3-5年内仍需注射小剂量的胰岛素,而间充质干细胞与胰岛细胞联合,不仅具有免疫调节作用还能分泌营养因子促进胰岛细胞活性和功能,但其在体内的致瘤性以及促进肿瘤细胞转移这些潜在不良反应会一定程度影响其临床应用.本文就间充质干细胞与胰岛细胞联合治疗1型糖尿病的免疫调节与营养活性作用及潜在不良反应方面进行简要综述.Islet transplantation for type 1 diabetes mellitus（T1DM） is limited by the lack of nutrients and presence of transplantation-associated in？ ammation.Most patients still need to be given a small dose of exogenous insulin in the following 3-5 years after islet transplantation.Cotransplantation of mesenchymal stem cells（MSCs） and islet holds great promise for the treatment of T1DM,because it can regulate the immune responses and overcome the shortage of trophic molecules.However,cotransplantation-associated tumorigenesis and the potential for metastasis in vivo should be also taken into consideration.In this review,we focus on the immunomodulatory properties,trophic effect and the potential side effects of cotransplantation of MSC and islet in the treatment of T1DM.

关 键 词：胰岛移植 间充质干细胞 1型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]